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Although interleukin-17 (IL-17) is the pre-eminent T-
cell-derived pro-inflammatory cytokine, its cellular
mechanism of action remains poorly understood. We ex-
plored novel signaling pathways mediating IL-17 induc-
tion of the cyclooxygenase-2 (COX-2) gene in human
chondrocytes, synovial fibroblasts, and macrophages. In
preliminary work, recombinant human (rh) IL-17 stim-
ulated a rapid (5–15 min), substantial (>8-fold), and sus-
tained (>24 h) increase in COX-2 mRNA, protein, and
prostaglandin E2 release. Screening experiments with
cell-permeable kinase inhibitors (e.g. SB202190 and p38
inhibitor), Western analysis using specific anti-phos-
pho-antibodies to a variety of mitogen-activated protein
kinase cascade intermediates, co-transfection studies
using chimeric cytomegalovirus-driven constructs of
GAL4 DNA-binding domains fused to the transactiva-
tion domains of transcription factors together with
Gal-4 binding element-luciferase reporters, ectopic
overexpression of activated protein kinase expression
plasmids (e.g. MKK3/6), or transfection experiments
with wild-type and mutant COX-2 promoter constructs
revealed that rhIL-17 induction of the COX-2 gene was
mediated exclusively by the stress-activated protein ki-
nase 2/p38 cascade. A rhIL-17-dependent transcriptional
pulse (1.76  0.11-fold induction) was initiated by ATF-
2/CREB-1 transactivation through the ATF/CRE en-
hancer site in the proximal promoter. However, steady-
state levels of rhIL-17-induced COX-2 mRNA declined
rapidly (<2 h) to control levels under wash-out condi-
tions. Adding rhIL-17 to transcriptionally arrested cells
stabilized COX-2 mRNA for up to 6 h, a process compro-
mised by SB202190. Deletion analysis using transfected
chimeric luciferase-COX-2 mRNA 3-untranslated region
reporter constructs revealed that rhIL-17 increased re-
porter gene mRNA stability and protein synthesis via
distal regions (545 to 1414 bases) of the 3-untrans-
lated region. This response was mediated entirely by the
stress-activated protein kinase 2/p38 cascade. As such,
IL-17 can exert direct transcriptional and post-tran-
scriptional control over target proinflammatory cyto-
kines and oncogenes.
Human interleukin-17 (IL-17),1 previously referred to as cy-
totoxic T-cell lymphocyte-associated antigen 8 (CTLA 8), is a
widely recognized prototypic CD45RO T-cell (CD4)-de-
rived pro-inflammatory cytokine (1–3). The IL-17 gene is ex-
pressed as a 155-amino acid chain that is glycosylated and
manifests biological activity as a covalent homodimer (2). Re-
cent cloning and sequencing studies have led to the identifica-
tion of several genes (IL-17 B–F) that bear close homology to
IL-17, highlighted by four to six functionally conserved cys-
teines that adopt cysteine knot structural conformations (4–6).
The biological activity of the IL-17 homologs is believed to
overlap with that of IL-17 (4–6).
It has become increasing clear that interleukin-17 occupies
an important place in the hierarchy of proinflammatory cyto-
kines associated with inflammatory, immune, malignant, and
arthritic diseases (reviewed in Refs. 7 and 8). Indeed, there is
now wide agreement, based on in vitro and in vivo studies, that
the T-cell-derived cytokine may play a fundamental role in the
pathophysiology of rheumatoid arthritis (RA) and possibly os-
teoarthritis (OA) (7–10). The cytokine is found in high levels in
the synovial fluid of RA and OA patients, and synovial tissues
express and produce abundant IL-17 (11–13), likely from infil-
trating T-cell populations. The gamut of target genes and cells
include the IL-17-dependent stimulation of the pro-inflamma-
tory cytokines TNF- and IL-1 by infiltrating macrophages,
IL-6, IL-8, granulocyte-macrophage colony-stimulating factor,
GRO-, and ICAM-1 from mononuclear phagocytes, endothe-
lial cells and fibroblasts, matrix-destructive metalloproteases
(e.g. collagenases and aggrecanases) from activated synovial
fibroblasts and cartilage chondrocytes, NO from endothelial
cells and chondrocytes, and inflammatory modulators such as
eicosanoids (e.g. PGE2) from may sources (14–22). Thus, IL-17
stimulates tissue damage and cartilage degradation (joint fail-
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ure) directly or indirectly by recruiting activated inflammatory
cells (e.g. neutrophils via adhesion molecules) and inducing the
synthesis of proinflammatory cytokines in the inflamed tissue.
The effector cascades mediating the proinflammatory actions
of IL-17 are currently under study, and although the IL-17
receptor (IL-17R) is a type I transmembrane protein (130 kDa)
with no intrinsic kinase activity (23), it can transduce a signal
through the activation of protein kinase A (PKA), JNK,
ERK1/2, JAK/STAT, and the NF-B cascades (20, 24–27). In-
terleukin-17-treated bovine chondrocytes express increased
levels of inducible nitric-oxide synthase mRNA, inducible ni-
tric-oxide synthase protein, and NO release, a process associ-
ated with PKA, ERK1/2, and, to a lesser extent, JNK activation
(20). Cyclooxgenase-2 mRNA expression and PGE2 release is
concomitant with the stimulation of JNK1 and JNK2 by IL-17
in bovine chondrocytes (20). Interleukin-17 activated release of
MMP-9 by human monocyte/macrophages followed a time
course coincident with the phosphorylation of ERK1/2 and the
transcription factors STAT1 and STAT3 (12). Using the same
cell and culture conditions, IL-17 stimulated macrophagic re-
lease of IL-1, TNF-, and IL-6 was related to rapid calcium
flux and a more delayed increase in NF-B DNA binding (14).
Studies using TRAF-2 or TRAF-6-deficient mouse embryonic
fibroblasts suggest strongly that TRAF6 is a critical mediator
of IL-17 signaling, implying the involvement of NF-B and/or
JNK cascades (26).
In the present study, we examined the IL-17-dependent sig-
naling events using as a paradigm the IL-17 induction of
COX-2 gene in human synovial fibroblasts, chondrocytes, and,
where indicated, macrophages. The COX-2 protein represents
the rate-limiting step in the activated biosynthesis of prosta-
noids, the latter playing a cardinal role as pleiotropic immune
and inflammatory modulators (28–30). The COX-2 gene is an
inducible immediate early gene regulated at both transcrip-
tional (promoter based) and post-transcriptional levels (31–33)
and, once induced, can be largely controlled by a positive feed-
back loop involving PGE2 (34). We report that the magnitude
and duration of the induction of COX-2 mRNA, COX-2 protein,
and PGE2 release by rhIL-17 is primarily the result of IL-17-
dependent stabilization of COX-2 mRNA, although transcrip-
tional mechanisms are also involved in the initial phase of
induction. Essentially, rhIL-17 mitigates COX-2 mRNA decay
normally mediated by the 3-UTR of COX-2 mRNA. Finally, we
provide evidence that the transcriptional and stabilization pro-
cesses involve a restricted MAPK profile, the MKK3/6/SAPK2/
p38 cascade.
EXPERIMENTAL PROCEDURES
Chemicals—Crystalline dexamethasone (9-fluoro-11,17,21-trihy-
droxy-16-methylpregna-1,4, diene-3, 20-dione), sodium fluoride, leupep-
tin, aprotinin, pepstatin, phenylmethylsulfonyl fluoride, actinomycin D,
dithiothreitol, sodium orthovanadate, and bovine serum albumin were
products of Sigma-Aldrich. NS-398 N-[2-(cyclohexyloxy)-4-nitrophenyl)-
methanesulfonamide], pyrrolidinedithiocarbamate, PGE2, L-N
6-(1-imi-
noethyl)lysine, 2HCl, PD98059, SB202190, KT-5720, phorbol 12-myris-
tate 13-acetate, forskolin, and rolipram were purchased from
Calbiochem (La Jolla, CA), whereas Bay 11-7082 was from Biomol
(Plymouth Meeting, PA). SDS, acrylamide, bis-acrylamide, ammonium
persulfate, and Bio-Rad protein reagent originated from Bio-Rad Lab-
oratories. Tris-base, EDTA, MgCl2, CaCl2, chloroform, Me2SO, anhy-
drous ethanol (95%), methanol (99%), formaldehyde, and formamide
were obtained from Fisher. rhIL-17, rhIL-10, rh interferon-, and rh
TNF- were purchased from R & D Systems (Minneapolis, MN). Dul-
becco’s modified Eagle’s medium (DMEM), phosphate-free and phenol
red-free DMEM, Trizol reagent, heat-inactivated fetal bovine serum,
and an antibiotic mixture (10,000 units of penicillin (base), 10,000 g of
streptomycin (base)) were products of Invitrogen.
Specimen Selection and Cell Culture—Synovial lining cells (human
synovial fibroblasts (HSF)) were isolated from synovial membranes
(synovia) and chondrocytes from articular cartilage. Both were obtained
at necropsy from donors with no history of arthritic disease (mean age,
30  27). Additional experiments were conducted with specimens ob-
tained from OA and RA patients undergoing arthroplasty who were
diagnosed based on the criteria developed by the American College of
Rheumatology Diagnostic Subcommittee for OA/RA (mean age, 67 
19) (35). Human synovial fibroblasts and chondrocytes were released by
sequential enzymatic digestion with 1 mg/ml Pronase (Roche Applied
Science) for 1 h, followed by 6 h with 2 mg/ml collagenase (type IA;
Sigma) at 37 °C in DMEM supplemented with 10% heat-inactivated
FCS, 100 units/ml penicillin, and 100 g/ml streptomycin (36–38).
Released HSF were incubated for 1 h at 37 °C in tissue culture flasks
(Primaria 3824, Falcon, Lincoln Park, NJ), allowing the adherence of
nonfibroblastic cells possibly present in the synovial preparation, par-
ticularly from OA and RA synovia. In addition, flow cytometric analysis
(Epic II, Coulter, Miami, FL), using the anti-CD14 (fluorescein isothio-
cyanate) antibody, was conducted to confirm that no monocytes/macro-
phages were present in the synoviocyte preparation (36–38). The cells
were seeded in tissue culture flasks and cultured until confluence in
DMEM supplemented with 10% FCS and antibiotics at 37 °C in a
humidified atmosphere of 5% CO2, 95% air. The cells were incubated in
fresh medium containing 0.5–1% fetal bovine serum for 24 h before the
experiments, and only second or third passaged HSF were used. Human
monocyte/macrophage cultures were prepared from the freshly drawn
blood of healthy volunteers as previously described (14).
Preparation of Cell Extracts and Western Blotting—50–100 g of
cellular protein extracted in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml
each of aprotinin, leupeptin, and pepstatin, 1% Nonidet P-40, 1 mM
sodium orthovanadate, and 1 mM NaF) or hot SDS-PAGE loading
buffer, from control and treated cells, were subjected to SDS-PAGE
through 10% gels (final concentration of acrylamide, 16  20 cm) under
reducing conditions and transferred onto nitrocellulose membranes
(Amersham Biosciences). Following blocking with 5% BLOTTO for 2 h
at room temperature and washing, the membranes were incubated
overnight at 4 °C with polyclonal anti-human COX-2 (Cayman Chemi-
cal Co., Ann Arbor, MI; 1:7500 dilution) in TTBS containing 0.25%
BLOTTO. The second anti-rabbit antibody-horseradish peroxidase con-
jugate (1:10,000 dilution) was subsequently incubated with membranes
for 1 h at room temperature, washed extensively for 30–40 min with
TTBS, and then rinsed with Tris-buffered saline at room temperature.
Following incubation with an ECL chemiluminescence reagent (Amer-
sham Biosciences), the membranes were prepared for autoradiography,
exposed to Kodak (Rochester, NY) X-Omat film, and subjected to a
digital imaging system (Alpha G-Imager 2000; Canberra Packard
Canada, Mississauga, Canada) for semi-quantitative measurements.
In addition to the anti-COX-2 and COX-1 (Cayman) antisera, the
following polyclonal antibodies were used (New England Biolabs Ltd.,
Mississauga, ON, Canada): total (independent of phosphorylation state)
and anti-phospho-p38 MAPK (Thr180/Tyr182), anti-phospho-MKK3/6
(Ser189/207), total and anti-phospho-IB- (Ser32), anti-phospho-ATF-2
(Thr69/71), anti-phospho-CREB-1 (Ser133), anti-phospho-c-Jun (Ser63), an-
ti-phospho-JNK/SAPK (Thr183/Tyr185), anti-phospho-Mnk1 (Thr197/201),
total and anti-phospho-eIF4E (Ser209), total and anti-phospho-p44/42
(Thr202/Tyr204), and total and anti-phospho-STAT3 (Ser727).
Northern Blot Analysis of mRNA—Total cellular RNA was isolated
(1 106 cells 10–20 g of RNA) using the Trizol (Invitrogen) reagent.
Generally, 5 g of total RNA were resolved on 1.2% agarose-formalde-
hyde gel and transferred electrophoretically (30 V overnight at 4 °C) to
Hybond-N™ nylon membranes (Amersham Biosciences) in 0.5 Tris/
acetate/EDTA buffer, pH 7. After prehybridization for 24 h, the hybrid-
izations were carried out at 50–55 °C for 24–36 h, followed by high
stringency washing at 68 °C in 0.1 SSC, 0.1% SDS. The following
probes, labeled with digoxigenin-dUTP by random priming, were used
for hybridization: human COX-2 cDNA (1.8 kb; Cayman Chemical Co.)
initially cloned into the EcoRV site of pcDNA 1 (Invitrogen) that was
released by PstI and XhoI digestion resulting in a 1.2-kb cDNA frag-
ment and a 780-bp PstI/XbaI fragment from GAPDH cDNA (1.2 kb;
American Type Culture Collection, Rockville, MD) that was initially
cloned into a PstI of pBR322 vector. This latter probe served as a control
of RNA loading because GAPDH is constitutively expressed in cells
used in these experiments. All of the blots were subjected to a digital
imaging system (Alpha G-Imager 2000; Canberra Packard Canada) for
semi-quantitative measurements, and changes in COX-2 expression
were always considered as a ratio, COX-2/GAPDH mRNA.
Transfection Experiments—Transient transfection experiments were
conducted in 4-, 6-, or 12-well cluster plates as previously described (34,
38). Transfections were conducted using the FuGENE 6TM (Roche Ap-
plied Science) or LipofectAMINE 2000TM reagents (Invitrogen) method
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for 6 h according to the manufacturers’ protocol with cells at around
30–40% confluence. The cells were re-exposed to a culture medium with
1% FCS for 2 h prior to the addition of the biological effectors. Trans-
fection efficiencies were controlled in all experiments by co-transfection
with 0.5 g of pCMV--gal, a -galactosidase reporter vector under the
control of CMV promoter (Stratagene, La Jolla, CA). A COX-2 promoter
(2390 to  34)-LUC plasmid was kindly provided by Dr. Stephen
Prescott (University of Utah) (39), and site-directed mutagenesis was
performed with the Bsu36I COX-2 promoter fragment (415 to  34)
using the QuikChangeTM (Stratagene) kit and involved modifying the
ATF-CRE site at bp 53/54 (CA 3 TC) and the NF-B site at bp
215/216 (CC 3 GG). Chimeric luciferase reporter plasmids fused
with the human COX-2 mRNA 3-UTR (1451 bp), AU-rich elements
(429 bp of which the first 116 bp contain an AU-cluster), the 3-UTR
minus the AU-rich element cluster, or a construct completely devoid of
the COX-2 3-UTR but containing the SV40 poly(A) signal (40). The
plasmids are designated LUC-3-UTR, LUC-ARE, LUC-ARE, LUC-
3-UTR, respectively, and were a kind gift of Dr. D. Dixon (University
of Utah).
In our signal transduction pathway reporting systems (Stratagene),
a reporter plasmid containing the 17-bp (5) GAL4 DNA-binding ele-
ment (UAS) fused to a TATA box upstream from the luciferase gene
(pFR-LUC) was co-transfected with a construct containing the transac-
tivation domains of transcription factors (e.g. ATF-2 and c-Jun) fused to
GAL4 DNA-binding domain and driven by a CMV promoter (e.g. pFA-
ATF-2). In addition, plasmids (Stratagene) harboring NF-B or inter-
feron-stimulated response element enhancer elements (5) fused to a
TATA box upstream from the luciferase gene were used to assess
transactivation processes activation by IL-17 in the cell phenotypes
tested. Finally, wild-type and activated MKK3/6 expression plasmids
(Stratagene) were overexpressed to determine the role on COX-2 ex-
pression. The luciferase values, expressed as enhanced relative light
units, were measured in a Lumat LB 9507 luminometer (EG&G,
Stuttgart, Germany) and normalized to the level of -galactosidase
activity (optical density at 450 nm after 24 h of incubation) and cellular
protein (bicinchoninic acid procedure; Pierce).
RT-PCR for Luciferase and GAPDH—The oligonucleotide primers
for PCR were prepared with the aid of a DNA synthesizer (Cyclone
Model, Biosearch Inc., Montreal, Canada) and used at a final concen-
tration of 200 nmol/liter. The sequences for the Luciferase primers were
as follows: 5-ACGGATTACCAGGGATTTCAGTC-3 and 5-AGGCTC-
CTCAGAAACAGCTCTTC-3 (antisense) for the luciferase fragment of
367 bp (40). The sequences for the GAPDH (which served as a standard
of quantitation) primers were 5-CAGAACATCATCCCTGCCTCT-3,
which corresponds to position 604–624 bp of the published sequence,
and 5-GCTTGACAAAGTGGTCGTTGAG-3, from positions 901–922
bp, for an amplified product of 318 bp (36). Two g of total RNA,
extracted with the Trizol reagent, was reverse transcribed and then
subjected to PCR as previously described (34). RT and PCR assays were
carried out with the enzymes and reagents of the GeneAmP RNA PCR
kit manufactured by PerkinElmer Life Sciences. Both the RT and PCR
reactions were done in a Gene ATAQ Controller (Amersham
Biosciences).
The amplification process was conducted over 10–30 cycles to define
the linear range of product amplification. The first cycle consisted of a
denaturation step at 95 °C for 1 min, followed by annealing and elon-
gation at 60 °C for 30 s, and 72 °C for 1.5 min, respectively. All subse-
quent cycles were executed under the same conditions, with the excep-
tion of the last cycle, where the elongation step was extended to 7 min.
We found a linear range (log luciferase/GAPDH versus log cycle num-
ber) between 10 and 17; as such we chose 11–13 cycles depending on the
type of experiment.
FIG. 1. Dose response (A) and time course (B) of rhIL-17 stim-
ulation of COX-2 protein and COX-2 mRNA. Cultured confluent
primary articular HC (1.2  106 cells in 6-well cluster plates) were
preincubated for 24 h in DMEM supplemented with 1% FCS plus
antibiotics at 37 °C to assure synchrony and quiescence. The cells were
then treated with increasing concentrations of rhIL-17 (0–200 ng/ml)
for 6 h (A) and for varying time periods (0–24 h) (B). Monolayers were
extracted for protein or RNA; 50 g of protein were analyzed for COX-2
protein by Western blotting using a specific polyclonal anti-COX-2
antiserum, whereas 5 g of total RNA were analyzed for COX-2 mRNA
by Northern hybridization using a specific digoxigenin-labeled cDNA
probe as described under “Experimental Procedures.”
FIG. 2. rhIL-17 stimulation of COX-2 protein and mRNA was
blocked by SAPK/p38 MAPK inhibitor (A) in a dose-dependent
fashion (B). Quiescent HC were treated with vehicle (C, lane 1) or with
10 ng/ml (570 pmol/liter) of rhIL-17 (lane 2) for 8 h in the presence of
either SB202190 (SB, 1 mol/liter), a p38 MAPK inhibitor; PD98059
(PD, 50 mol/liter), a MEK1/2 inhibitor; KT-5720 (KT, 2 mol/liter), a
PKA inhibitor; dexamethasone (DEX, 100 nmol/liter); NS-398 (NS, 100
nmol/liter), a preferential COX-2 inhibitor; pyrrolidinedithiocarbamate
(100 mol/liter), an oxygen radical scavenger; L-N6-(1-iminoethyl)l-
ysine, 2HCl (L-NIL, 1 mol/liter), an inducible nitric-oxide synthase
inhibitor; and Bay 11-7082 (BAY, 5 mol/liter), an IKK inhibitor. In B,
the cells were incubated with or without rhIL-17 in the absence or
presence of increasing concentrations of SB202190. Monolayers were
extracted for protein or RNA; 50 g of protein were analyzed for COX-2
protein by Western blotting using a specific polyclonal anti-COX-2
antiserum as described under “Experimental Procedures,” whereas 5
g of total RNA were analyzed for COX-2 mRNA and GAPDH mRNA by
Northern hybridization using specific digoxigenin-labeled cDNA
probes.
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FIG. 3. Time course of SAPK2/p38 MAPK cascade activation by rhIL-17. A and B, quiescent HC treated for varying time periods (0–16
h; 16C, 16 h of control) with 10 ng/ml (570 pmol/liter) of rhIL-17 (top panels). Monolayers were extracted for protein, and 50 g were analyzed for
total and phospho-SAPK2/p38 MAPK intermediates by Western blotting using specific rabbit polyclonal antisera: anti-phospho-p38 MAPK
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The PCR products were analyzed and verified by electrophoresis on
1.15% agarose gels in a Tris-borate-EDTA buffer system as previously
described (34). All gel photos were subjected to a digital imaging system
(see above) for semi-quantitative measurements, and the results were
expressed as a ratio of luciferase/GAPDH PCR fragments.
Extraction of Nuclear Proteins and EMSA Experiments—Confluent
control and treated cells in 4-well cluster plates (3–5  106 cells/well)
were carefully scraped into 1.5 ml of ice-cold phosphate-buffered saline
and pelleted by brief centrifugation. The nuclear extracts were pre-
pared as previously described (36).
Double-stranded oligonucleotides containing wild-type and mutant
sequences were from Invitrogen, annealed in 100 nM Tris-HCl, pH 7.5,
1 M NaCl, 10 mM EDTA buffer at 65 °C for 10 min, cooled for 1–2 h at
room temperature, and finally end-labeled with [-32P]ATP using T4
polynucleotide kinase (Promega, Madison, WI). The sense sequences of
the oligonucleotides tested were as follows: NF-B (COX-2), 5-CAG
GAG AGT GGG GAC TAC CCC CTC TGC TC-3; NF-B mut, 5-CAG
GAG AGT GGC GAC TAG GCC CTC TGC TC-3; ATF/CRE (COX-2),
5-GGC GGA AAG AAA CAG TCA TTT CGT CAC ATG GGC TTG G-3;
ATF/CRE mut, 5- GGC GGA AAG AAA CAG TCA TTT CGT TCC ATG
GGC TTG-3; NF-IL6, 5-CTA GGG CTT GCG CAA TCT ATA TTC G-3;
and NF-IL6 mut, 5-CTA GGG CTT GCT ACC CCT ATA TTC G-3.
Binding buffer consisted of 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5
mM dithiothreitol, 0.5 mM EDTA, 1 mM MgCl2, 4% glycerol, and 2.5 g
of poly(dI-dC). The binding reactions were conducted with 15 g of
nuclear extract ( 1 g c/EBP/// antibodies in supershift analysis)
and 100,000 cpm of 32P-labeled oligonucleotide probe at 22 °C for 20 min
in a final volume of 10 l. The binding complexes were resolved by
nondenaturing polyacrylamide gel electrophoresis through 6% gels in a
Tris-borate buffer system, after which the gels were fixed, dried, and
prepared for autoradiography.
Statistical Analysis—All of the results were expressed as the
means  S.D. or the means and the coefficient of variation of three to
five separate experiments as indicated. The transfection experiments
were performed in triplicate. Statistical treatment of the data was
performed parametric (Student’s t test) or by nonparametric (Mann-
Whitney) analysis if Gaussian distribution of the data could not be
confirmed. Significance was acknowledged when the probability that
the Null Hypothesis was satisfied at 5%.
RESULTS
Recombinant Human IL-17 Induction of COX-2 mRNA Ex-
pression and Synthesis: Time and Dose Dependence—To better
characterize the properties of IL-17 cell signaling, we per-
formed both dose response and time course studies on the
induction of the COX-2 gene. As shown in Fig. 1A, the EC50 for
rhIL-17-dependent COX-2 protein synthesis in our HC culture
system was 	10 ng/ml (n  3), and as such, this concentration
was chosen for all subsequent experimentation unless other-
wise indicated. Time course studies revealed that increases in
COX-2 mRNA expression reached 2.1-fold at 15 min and
greater than 7-fold after 2 h, attained steady state at 4–8 h,
and thereafter declined very gradually for the next 16 h as
shown in Fig. 1B. In fact, COX-2 mRNA was detectable within
5 min after rhIL-17 treatment (data not shown). The induction
of COX-2 protein was perceptible within 30 min following stim-
ulation with rhIL-17 and thereafter followed a pattern of bio-
synthesis closely resembling COX-2 mRNA expression. Similar
experiments conducted with HSF and human macrophages
yielded identical results (data not shown). The rhIL-17-stimu-
lated PGE2 release profile indicated that eicosanoid levels were
increased after 1 h and by 24 h more than 30 ng/106 cells were
detected (n  3).
SAPK2/p38 MAPK Activity and rhIL-17-dependent Regula-
tion of COX-2 Gene Expression—Previous studies in our labo-
ratory and others demonstrate that IL-17 may signal through
activation of MAPK (e.g. p44/42 MAPK) and/or NF-B cas-
cades, although it is presently unclear how the COX-2 gene
responds (12, 14, 20). To delineate post-receptor signaling path-
ways activated by IL-17, we chose, as a first approach, to use
cell-permeable chemical inhibitors. As shown in Fig. 2A,
SB202190 (SB, SAPK2//p38/ MAPK inhibitor) suppressed
rhIL-17-induced COX-2 mRNA and protein synthesis by 	90%
(87  9%, mean  S.D., n  4); PGE2 release was suppressed
by greater than 95% (data not shown). The MEK1/2 inhibitor
PD98059, and the IB kinase inhibitor, Bay 11-7802 were
without significant effect, whereas the PKA inhibitor KT-5720
had a modest albeit inconsistent inhibitory activity. The clini-
cally useful anti-inflammatory steroid, dexamethasone com-
pletely suppressed rhIL-17-induced COX-2 mRNA and protein
synthesis, whereas pyrrolidinedithiocarbamate and L-N6-(1-
iminoethyl)lysine, 2HCl, inhibitors of reactive oxygen radicals
and nitric oxide production respectively, were seemingly with-
out effect (Fig. 2A). We previously reported that IL-1 induction
of the COX-2 gene was mediated by a PGE2-dependent feed-
forward mechanism and as such could be abrogated by co-
incubating IL-1 with a preferential COX-2 inhibitor like NS-
398 (34). The present data show that NS-398 does not block to
any significant degree the rhIL-17 induction of the COX-2 gene
(Fig. 2A). Identical results were obtained with HSF in culture
(data not shown).
Given the apparent role of SAPK2/p38 in the induction of
COX-2 by rhIL-17, we endeavored to determine the degree of
sensitivity of the inductive process to SB202190 by carefully
controlled dose-response studies. As shown in Fig. 2B, the
inhibitor blocked rhIL-17 stimulation of steady-state levels of
COX-2 mRNA in a dose-dependent fashion, and the IC50, cal-
culated by plotting the log optical density COX-2/GAPDH
mRNA versus the concentration of SB202190, was 36  4 nM
(n  3).
Cell Signaling by rhIL-17 Is Restricted to the SAPK2/p38
MAPK Cascade—To pursue further the results obtained with
regard to rhIL-17 and SAPK2/p38 activation, we performed
additional investigative experimentation. As shown in Fig. 3A,
rhIL-17 triggered a bi-phasic pattern of MKK3/6 (Ser189/207)
and SAPK2/p38 phosphorylation with the initial phase reach-
ing a zenith at 20 min and then falling to essentially control
levels within the next 40 min (i.e. 1 h post-stimulation). The
second phase was initiated within the next 60 min (i.e. 2 h
post-stimulation) and attained a maximum at 8 h. There were
no changes in the cellular protein level of SAPK2/p38 (Fig. 3A).
In addition, ATF-2, a transcription factor whose transcriptional
activity is modulated by phosphorylation at Thr69 and Thr71 by
SAPK2/p38 (41), was phosphorylated at the latter sites in a
time course essentially identical to that of SAPK2/p38/MKK3/6
(Fig. 3A). A similar pattern was observed with CREB-1/ATF-1
(Ser133) phosphorylation following IL-17 stimulation, although
the second phase was less evident. Fragmentation of both
SAPK2/p38 and ATF-2 was observed in the initial phosphoryl-
ation phase. The downstream kinases MAPK-APK2 and MSK1
(Thr180/Tyr182), anti-phospho-MKK3/6 (Thr180/Tyr182), anti-phospho-Mnk1 (Thr197/202), anti-phospho-eIF-4E (Ser209), anti-phospho-CREB-1
(Ser133), and anti-phospho-ATF-2 (Thr69/71). In C, the cells were treated with 10 ng/ml (570 pmol/liter) of rhIL-17 in the absence or presence of 0.1
M of SB202190 for 0, 0.33, 1, and 2 h, after which time the cell extracts were prepared for Western blotting (top panel) using anti-phospho-Mnk1
(Thr197/202), anti-phospho-eIF-4E (Ser209), and total anti-eIF-4E. Bottom panel, densitometric scanning was performed on Western blots (average
of two determinations with a coefficient of variation of 11.3%). In D, the cells were plated at 40% confluence in DMEM supplemented with 10%
heat-inactivated FCS, 100 units/ml penicillin, and 100 g/ml streptomycin and transfected with 50 ng each of pCMV, pFCMKK3, pMKK3, or
pMKK3 in the presence of 0.1 M of SB202190. The cells were lysed after 24 h, and COX-2 and COX-1 were analyzed by Western blotting using
specific antisera as described under “Experimental Procedures.”
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were not phosphorylated by rhIL-17 treatment, although the
pro-inflammatory cytokine rhIL-1 phosphorylated both (data
not shown). The MAPK signal-integrating kinase-1 (Mnk1) and
its putative substrate, the eukaryotic initiation factor 4E (eIF-
4E), were avidly phosphorylated by rhIL-17 at Thr197/202 and
Ser209, respectively (Fig. 3B). The latter rhIL-17-induced post-
translational modifications were substantially blocked in the
presence of SB202190 (Fig. 3C). Finally, overexpression of a
constitutively activated MKK3 construct (pMKK3) stimu-
lated COX-2 protein synthesis, an effect completely abrogated
by SB202190 (Fig. 3D).
To confirm whether rhIL-17 could increase the transactiva-
tional capacity of ATF-2, we conducted experiments in which a
luciferase reporter construct harboring 5-flanking GAL4 DNA-
binding elements (5) was co-transfected with a chimeric plas-
mid containing the N-terminal (1–96) ATF-2 transactivation
domain fused to GAL4 DNA-binding domain and driven by a
CMV promoter. When the cells were then incubated with
rhIL-17 for 6 h, a 5.3  0.7 increase (n  3, mean  S.D.) in
luciferase activity was observed (Fig. 4A), an effect completely
blocked by co-incubations with SB202190 (control, 2808  312
RLU; SB202190, 2689  675 RLU). This response was quite
specific because when co-transfections were performed with
chimeric constructs containing the transactivation domain of
c-Jun (1–223), c-Fos (206–313), or Elk-1 (307–428), no in-
creases in luciferase activity were observed following rhIL-17
stimulation. In contrast, phorbol 12-myristate 13-acetate po-
tently stimulated transactivation by c-Fos and c-Jun, whereas
rhIL-1 activated the transactivational capacity of Elk1 (Fig.
4B). Interestingly, rhIL-17 stimulated reporter transactivation
by CREB by a modest but statistically significant 2.1  0.2,
whereas the combination of forskolin (adenylate cyclase acti-
vator) and rolipram (cAMP-dependent phosphodiesterase type
IV inhibitor) provoked a 6.2  0.45 (n  3, mean  S.D.)
increase (Fig. 4A). The absence of induction by rhIL-17 of
c-Jun, c-Fos, or Elk-1 transactivational activity was supported
by the observations that the cytokine had little or no effect (in
contrast to rhIL-1) on the phosphorylation (activity) of the
signaling intermediates ERK1/2 and JNK, which are known to
phosphorylate and increase the transactivational capacity of
the latter transcription factors (42, 43) (Fig. 4C).
Many studies have suggested that the IL-17 signal is trans-
duced by the JAK/STAT and NF-B cascades in a variety of cell
types (12, 20, 25). To address this issue in the context of our cell
culture models and the control of COX-2 gene expression, we
measured the phosphorylation (activation) state of critical in-
termediates and performed transactivational analysis with re-
porter constructs. As shown in Fig. 5A, rhIL-17 weakly stimu-
lated the phosphorylation of IB-, which reached a maximum
after 10 min with no measurable change in total cellular IB-.
In contrast, TNF-, a prototypical pro-inflammatory cytokine
FIG. 4. rhIL-17 stimulation of ATF-2/CREB-1 transactivation.
HSF were plated in 12-well cluster plates at 30% confluence in complete
medium and then co-transfected with 1 g of pFC-LUC reporter, 0.5 g
of pCMV--gal, and 50 ng each of pFA-CMV, pFA-ATF-2, pFA-CREB-1
(A), pFA-c-Jun, pFA-c-Fos, or pFA-Elk-1 (B) as described under “Exper-
imental Procedures.” After 24 h, the cells were stimulated for 6 h with
or without rhIL-17 (10 ng/ml) or forskolin (60 mol/liter) and rolipram
(100 mol/liter), phorbol 12-myristate 13-acetate (200 nmol/liter), or
rhIL-1 (100 pg/ml) as indicated in Fig. 3. The cells were lysed, and the
luciferase activity, -gal activity, and protein content were determined
as described under “Experimental Procedures.” The values are ex-
pressed as the means  S.D. of three determinations in triplicate of
luciferase activity (relative light units) divided by -gal activity (optical
density). Probabilities (p) were performed by Student’s t test. In C,
quiescent HC were treated for 20 min with rhIL-17 (0–200 ng/ml) or
rhIL-1 (10 or 100 pg/ml). Monolayers were extracted for protein, and
50 g were analyzed for total and phospho-ERK1/2 (p42/44) or phospho-
JNK (p46/p54) by Western blotting using specific rabbit polyclonal
antisera.
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and potent activator of the NF-B cascade potently induced
IB- phosphorylation in less than 2 min with a concomitant
reduction in total IB- of more than 50%. Interleukin-17 stim-
ulated a time-dependent phosphorylation of the transcription
factor STAT3 (but not STAT1) with detectable Ser727 phospho-
rylation observed between 1–2 h, a zenith at 4 h, and gradual
decay thereafter. The prototypic STAT inducer IL-10 caused a
similar magnitude of phosphorylation but much sooner (after
20 min) (Fig. 5B). Furthermore, although TNF- stimulated a
7–10-fold increase in luciferase activity in cells transfected
with a reporter construct harboring five tandem NF-B con-
sensus sequences, rhIL-17 had no statistically significant effect
(Fig. 5C). However, when identical protocols were repeated in
transiently transfected HSF, rhIL-17 increased reporter activ-
ity by 1.78  0.31-fold (n  4 determinations). 6 h post-stimu-
lation, rhIL-10, interferon- and rhIL-17 all increased lucifer-
ase activity to a significant degree in cells transfected with a
reporter construct harboring five interferon-stimulated re-
sponse element tandem sequences (Fig. 5C).
COX-2 Promoter Studies—To examine for elements of tran-
scriptional control of the COX-2 gene via rhIL-17-stimulated
SAPK2/p38 signaling, we conducted transient transfection
analyses with a 416-bp (Bsu36I site) human COX-2 promoter
construct harboring enhancer elements (44, 45) for critical
transcription factors including a ATF/CRE site (58 to 53).
We observed that rhIL-17 (10 ng/ml) stimulated a human
COX-2 promoter-luciferase reporter construct by 1.76  0.11
(mean  S.D., n  3–5)-fold (Fig. 6A). SB202190 abolished the
induction completely (control, 11,739  1,452 versus rhIL-17,
20,660  1,291; rhIL-17  SB202190; 7,635  987 RLU).
Companion experiments with a ATF/CRE mutant plasmid (see
“Transfection Experiments” under “Experimental Procedures”)
revealed that the reporter activity was considerably lower than
wild-type promoter plasmid (mutant, 6,722  911 versus wild
type (control), 11,739  1,452 RLU, mean  S.D., n  3) and
was refractory to rhIL-17 (compare 6,722 911 versus rhIL-17,
6,945  753 RLU, mean  S.D., n  3). To assess the role of
ATF-2 in transcriptional activation of the COX-2 promoter, we
used a previously described decoy strategy (46) in which the
chimeric plasmid containing the N-terminal (1–96) transacti-
vation domain of ATF-2 fused to the GAL4 DNA-binding do-
main was overexpressed prior to rhIL-17 stimulation. As can be
seen in Fig. 6A, rhIL-17 induction of luciferase activity was
completely suppressed, and indeed luciferase activity was ob-
served to be below control values. Forced expression of other
transcription factor-GAL4 chimers were without effect with the
exception of pFA-CREB, where 30.3  3.15%of rhIL-17-stimu-
lated luciferase activity was blocked (Fig. 6A).
Mutating the more proximal NF-B site (223/214) in the
human COX-2 promoter construct was without effect in terms
of basal and IL-17-stimulated luciferase activity (control,
10,639  1,975 versus rhIL-17, 18,332  2,070 RLU; 1.72 
0.13-fold increase, n  3; compare with wild type; see above)
when transfections were performed with human chondrocytes.
However, when HSF were used with the same protocol, basal
reporter activity was reduced but not the level of rhIL-17 in-
duction (control, 8,117  1,424 versus rhIL-17, 14,998  2,114
RLU; 1.85  0.14-fold increase).
EMSA experiments using 32P-labeled ATF/CRE (COX-2) ol-
igonucleotides indicated a high level of endogenous nuclear
protein binding that was increased with rhIL-17 treatment
(Fig. 6B, upper panel). Basal and induced binding was dis-
placed by adding 10-fold excess cold oligonucleotide but not by
the mutant oligonucleotide (see above ATF/CRE mutant COX-2
promoter studies). Furthermore, the addition of SB202190 ab-
rogated induced and, to a large extent, basal oligonucleotide
binding. Confirming promoter studies, rhIL-17 stimulation of
human chondrocytes produced no increases in 32P-labeled
NF-B (COX-2) oligonucleotide binding in contrast to TNF-
FIG. 5. Role of NF-B and JAK/STAT cascades as mediators of
rhIL-17 induction of the COX-2 gene. Quiescent confluent HC were
treated with 10 ng/ml of rhIL-17 from 0 to 240 min or for 2 min with 10
ng/ml of TNF- (A). Alternatively the cells were exposed to 10 ng/ml of
rhIL-17 for 0–16 h or with rhIL-10 (1 ng/ml) for 20 min (B). Monolayers
were extracted for protein and prepared for Western blotting and
probed with specific anti-phospho-IB- and anti-IB- (A) or anti-
phospho-STAT3 and anti-STAT3 (B) antibodies as indicated. The blots
are representative of three separate experiments that gave essentially
identical results. In C, the cells were transfected with 1 g each of
either 5 NF-B-tatata-LUC or 5 interferon-stimulated response el-
ement-tatata-LUC and 0.5 g of pCMV--gal as described under “Ex-
perimental Procedures.” The cells were then exposed to either rhIL-17
(10 ng/ml), rhTNF- (10 ng/ml), rhIL-10 (1 ng/ml), or interferon- (1
ng/ml) for 6 h. The cells were lysed and prepared for measurement of
luciferase activity, -gal activity, and protein content as described un-
der “Experimental Procedures.” The values are expressed as the
means  S.D. of four determinations in triplicate of luciferase activity
(relative light units) divided by -gal activity (optical density). Proba-
bilities (p) were performed by Student’s t test.
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(Fig. 6B, middle panel). The human COX-2 promoter harbors a
proximal NF-IL-6 site that binds c/EBP transcription factors as
either homodimers or heterodimers with other transcription
factors (e.g. NF-B) and can increase transcriptional activation
(44, 45). Time course studies revealed that rhIL-17 increased
NF-IL-6 binding after 30 min, reached a zenith after 60 min,
and thereafter declined so that at 90 min binding to the oligo-
nucleotide was similar to controls (Fig. 6B, lower panel). Su-
pershifts with antibodies to the different isoforms of c/EBP (see
“Experimental Procedures”) confirmed the presence of c/EBP
only (data not shown).
Interleukin-17 Stabilizes COX-2 mRNA—Judging by the ac-
cumulated data (see above), it is unlikely that IL-17 modifies
steady-state COX-2 mRNA expression in our cell culture mod-
els exclusively at the transcriptional level. As such we exam-
ined post-transcriptional mechanisms involving strictly mes-
sage stabilization and protein synthesis. As a first approach,
we employed classical techniques involving measuring COX-2
mRNA in transcriptionally arrested cells (actinomycin D) in
the absence or presence of rhIL-17. We had previously reported
(34) that when HSF are activated with rhIL-1 for 3–4 h
(steady state) followed by wash-out and a fresh change of
medium, the elevated levels of COX-2 mRNA declined rapidly
such that within 2 h the levels were similar to control non-
stimulated cells (t1⁄2  0.85 h). However, if PGE2 was added to
fresh medium (in the presence of actinomycin D), COX-2
mRNA levels remained elevated (t1⁄2  13 h) (34). Similarly, as
represented in Fig. 7, rhIL-17 stabilized COX-2 mRNA and
increased its half-life to 	5.8 h, based on multiple linear re-
gressions of optical density of COX-2 mRNA versus time (n 3,
y  1.1–0.095x). The stabilizing effect was abrogated by co-
incubations with SB202190. We included PGE2 in these exper-
iments as a positive control and for purposes of comparison.
As mentioned earlier, the COX-2 mRNA has multiple copies
of the Shaw-Kamen AU-rich sequences that are believed to
influence message stability. Recent studies (40, 47) have pro-
vided evidence that the AU-rich elements (6) in the first 116 bp
of the 3-UTR may mediate COX-2 mRNA instability, whereas
we recently reported that proximal but also distal sequences
mediate PGE2-dependent stabilization (34). To determine
whether rhIL-17-dependent COX-2 mRNA stabilization was
manifested through the 3-UTR sequences, we transfected HSF
with CMV-driven chimeric expression constructs containing
luciferase cDNA (reporter) fused 3 to the human COX-2–3-
UTR (Luc3-UTR), AU-rich region (LucARE), AU-deleted re-
gion (LucARE-3-UTR), or complete removal of the 3-UTR
region (Luc 3-UTR). As shown in Fig. 8A, cells transfected
with Luc 3-UTR were refractive to any kind of modulation.
However, rhIL-17 increased luciferase activity 3–4-fold (n  5)
in cells transfected with Luc3-UTR and LucARE-3-UTR con-
structs but not with LucARE. If the cells were washed out,
and fresh medium was added, luciferase activity decreased
dramatically after 4 h. The latter decrease could be mitigated
with the addition of rhIL-17, a response that was apparently
SAPK2/p38-mediated as the induction was abrogated by co-
incubations with SB202190. We obtained similar results with
PGE2, included as a positive control, with the sole difference
being that the ARE-rich region of the 3-UTR is also sensitive
to eicosanoid stimulation (Fig. 8A).
Although COX-2 mRNA stabilization and protein synthesis
are closely coupled in our cell culture models, we verified
FIG. 6. rhIL-17 induction of the COX-2 promoter is dependent
on SAPK2/p38 MAPK activation and ATF-2 transactivation (A).
EMSA profiles of rhIL-17 stimulated DNA binding proteins (B). HSF
were plated in 12-well cluster plates at 30–40% confluence in complete
medium and then co-transfected with 1 g of a human COX-2 promoter
construct containing a portion of the proximal promoter fused to a
luciferase reporter construct (Bsu36I fragment, 415, phCOX-2-LUC
reporter), 0.5 g of pCMV--gal, and 50 ng each of pFA-CMV, pFA-
ATF-2, pFA-CREB-1, pFA-c-Jun, pFA-c-Fos, and pFA-Elk-1 as de-
scribed under “Experimental Procedures.” After 24 h, the cells were
stimulated for 6 h with rhIL-17 (10 ng/ml) and lysed, and the luciferase
activity, -gal activity, and protein content were determined as de-
scribed under “Experimental Procedures.” The values are expressed as
the means  S.D. of three to five determinations in triplicate of lucif-
erase activity (relative light units) divided by -gal activity (optical
density). Probabilities (p) were performed by Student’s t test. In B,
nuclear extracts were prepared from human chondrocytes treated as
indicated (Con, control), and 15 g of protein were incubated with
32P-labeled ATF/CRE (top panel), NF-B (middle panel), or NF-IL6
(bottom panel) oligonucleotides for 20 min at 22 °C. The binding reac-
tion mixtures were subject to EMSA analysis as described under “Ex-
perimental Procedures.”
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whether our reporter system (i.e. luciferase protein (activity)
and mRNA) exhibited similar coordination. As shown in Fig.
8B, in cells transfected with Luc3-UTR and stimulated with
rhIL-17, luciferase mRNA decayed rapidly under wash-out con-
ditions but was stabilized with the addition of rhIL-17. Densi-
tometric scanning analysis (n  4) revealed a t1⁄2 for luciferase
mRNA of under wash-out conditions of about 0.78 h (y 
2.15–1.38x) and t1⁄2 in the presence of rhIL-17 of 	6.2 h (y 
2.4–0.195x). As shown in Fig. 8B, the addition of SB202190
blocked the stabilizing effect of rhIL-17.
DISCUSSION
The preponderance of data suggests that IL-17 is integrated
into the immune and inflammatory response at a much higher
level of hierarchy than previously thought. In inflammatory
diseases like RA, T-cells infiltrate the synovial membrane, and
tissue pathogenesis occurs through complex cell-cell and cell-
humoral interactions (48–50). In this model, T-cells initiate the
inflammatory cascade by producing, among other factors,
IL-17, which provokes resident target cells to produce proin-
flammatory cytokines, chemokines, adhesion molecules, ma-
trix destructive metalloproteases, acute phase proteins, lipid
mediators, and free radicals.
Normally not expressed in quiescent connective tissue cells
or monocytes, the elevated levels of COX-2 mRNA, COX-2
protein, and PGE2 release observed in arthritis-affected syno-
vial membranes have also been associated etiologically with
the disease process (29, 30, 51). It has been suggested that the
synovium, whether in a disease or normal state, is a PGE2-de-
pendent tissue and that COX-2 behaves as a “master control
gene” (34, 52). Thus, understanding the mechanisms responsi-
ble for dysregulated COX-2 expression is of considerable clini-
cal concern, and the role of IL-17 in this regard takes on added
significance from a therapeutic perspective.
To our knowledge, this is the first report associating IL-17
action with post-transcriptional/translational control of any
target gene, although the SAPK/p38 pathway is connected with
both levels of control as was shown previously (33, 34, 47, 53).
The bi-phasic pattern of MKK3/6/SAPK/p38/ATF-2 phosphoryl-
ation induced by rhIL-17 was observed previously with rhIL-
1, and the second phase was attributed to ambient accumu-
lation of PGE2 (34). A bifurcation of the IL-17-induced
signaling pathway to Mnk1 occurs in a slower time frame
(maximum 1 h) than MKK3/6/SAPK/p38/ATF-2 but is coinci-
dent with the Ser209 phosphorylation of the CAP (N7-methyl-
guanosine)-binding protein, eIF-4E. The latter post-transla-
tional modifications of both Mnk1 and eIF-4E were apparently
p38 MAPK-dependent and suggested a link between IL-17
action and translational control. However, because the role of
eIF-4E phosphorylation in translational control mechanisms is
unclear (54–56), and more targeted experimentation is re-
quired, such a suggestion would be premature. Perhaps para-
doxically, phosphorylation of eIF4E is sometimes associated
with a global inhibition of protein synthesis observed during
cell stress or serum deprivation (57–59). This would provide a
reasonable explanation for the conspicuous phosphorylation of
eIF4E after 16 h in our quiescent cultures (1% serum) both in
control and rhIL-17-treated wells (Fig. 3B).
Previous studies, using transformed cell lines for the most
part, emphasized the role of proximal, AU-rich containing se-
quences in mediating COX-2 mRNA instability (60–63). Pro-
inflammatory cytokines, through SAPK/p38 activation, in-
crease steady-state levels of COX-2 mRNA by stimulating the
production of cognate RNA-binding proteins (e.g. HuR) that
mitigate, through sequence-specific binding, mRNA degrada-
tion (Ref. 60; reviewed in Ref. 64). The precise mechanisms,
however, remain ill-defined. We find that distal sequences were
exclusively reactive to the stabilizing effects of IL-17 both in
terms of mRNA (stabilization) and protein synthesis in our
primary cell culture models. Indeed, the absence of the AU-rich
element (123 nucleotides) had no effect on IL-17-dependent
stabilization. Thus, the IL-17-modulated RNA-binding protein
repertoire is likely to be different from that of other cytokines.
In transient transfections of HSF with expression constructs of
known RNA-binding proteins (AUF1, HuR, and tristetrapro-
lin), only tristetraprolin destabilized distal COX-2–3-UTR re-
porter constructs (65).2 Interestingly, tristetraprolin is tar-
geted by SAPK/p38 for phosphorylation (60), which may alter
its RNA binding properties and function.
There are a number of cis-elements found in the promoter
region of the COX-2 gene that may exert transcriptional control
of which ATF/CRE, c/EBP (132/124), and both NF-B sites
(223/214 and 445/427) are the best studied (44, 45, 66).
In our cell culture models, mutating the ATF/CRE site alone, is
apparently sufficient to abrogate IL-17 induction of COX-2
promoter activity and also to reduce basal promoter activity
compared with wild type. In many cell types, the ATF/CRE site
is activated by homodimers and heterodimers of c-Jun, c-Fos,
and ATF/CREB family members subsequent to serum, 12-O-
tetradecanoylphorbol-13-acetate, or growth factor stimulation
(66, 67). However, rhIL-17 does not stimulate the transactivat-
ing capacities of Fos/Jun proteins but clearly favors those of
ATF-2 and CREB-1. Decoy ATF-2 overexpression reduced all of
the induced (partial reduction with CREB-1) and some of the
basal COX-2 promoter activity, although this does not neces-
2 W. H. Faour, A. Mancini, Q. W. He, and J. A. Di Battista, unpub-
lished observations.
FIG. 7. rhIL-17 stabilizes COX-2 mRNA: role of SAPK2/p38
MAPK. Quiescent HSF were treated with vehicle (lane C) or with 10
ng/ml of rhIL-17 for 6 h (steady state), after which time cells were
washed out and treated with actinomycin D (1 g/ml) for 30 min, and
then fresh medium was added containing either vehicle (Wo), rhIL-17
(10 ng/ml), rhIL-17  SB202190 (0.1 M), or PGE2 (100 nmol/liter).
After an additional 2 (short) or 8 h (long) of incubation, monolayers
were extracted for RNA at each time point, and 5 g of total RNA were
analyzed for COX-2 mRNA and GAPDH mRNA by Northern hybridiza-
tion using specific digoxigenin-labeled cDNA probes.
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sarily mean that ATF-2 homodimers exclusively transactivate
the COX-2 promoter at the ATF/CRE; such results could be
obtained if ATF-2-containing heterodimers were binding. Judg-
ing by our EMSA studies, there is considerable basal binding
activity at the COX-2 ATF/CRE site, which is not surprising
given that ATF-2 is expressed constitutively at significant lev-
els both in its native and, to a lesser extent, phosphorylated
forms in our cell cultures (see also Ref. 41). Induced binding by
IL-17 was modest (although significant), and this may be a
reflection of the fact that IL-17 activation of the COX-2 pro-
moter was less than 2-fold. More focused experiments would be
required to identify IL-17 induced ATF/CRE-binding transac-
tivating proteins.
As indicated above, several recent studies imply that the
IL-17 signal is transduced by the NF-B signaling cascade in a
number of different cell types (reviewed in Ref. 7). In the
present context, NF-B may mediate transcriptional induction
of the COX-2 gene by IL-17 in bovine chondrocytes (20). In
contrast, we showed here that in human chondrocyes/synovial
fibroblasts, IL-17-dependent activation of NF-B is delayed
and modest (compared with TNF-) and is not related tempo-
rally to COX-2 transcription, mRNA stabilization, or protein
synthesis. Basal COX-2 promoter activity was not affected
when the proximal NF-B site was mutated in transfections
using human chondrocytes, nor did the mutation abrogate
IL-17 induced COX-2 promoter activity. The situation differed
somewhat in HSF, because IL-17 can mildly stimulate NF-B
transactivation activity, although the mutation in the COX-2
proximal site did not compromise IL-17 induction of the COX-2
promoter. Furthermore, using stably transfected HSF overex-
pressing dominant-negative mutants of TRAF-2, TRAF6, or
IB-, IL-17 activation of a NF-B reporter was abrogated to
varying degrees but not the expression of COX-2 mRNA.3
Taken together, our data support the notion that the NF-B
signaling pathway does not play an important role in mediat-
ing a response in chondrocytes to the IL-17 signal. In support,
IL-17 induction of the COX-2 gene in human macrophages is
indirect (delayed) and is dependent on IL-17-induced TNF-
release, which in a feedback reaction (autocrine) activates
NF-B (14). Similar results were reported in osteoblasts where
IL-17 induction of inducible nitric-oxide synthase was medi-
ated by NF-B but only in combination with TNF- and not
with IL-17 alone (68).
Despite studies demonstrating that IL-17 can activate ERK
and JNK pathways in chondrocytes (20), we could not, under
carefully controlled conditions, reproduce these data in human
chondrocytes or synovial fibroblasts. Our experiments with
transactivation reporter systems show that downstream tran-
scription factors such as Elk1, c-Jun, or c-Fos were not acti-
vated in our connective tissue cell culture models. Admittedly
most of the previously reported studies were performed with
nonhuman cell types, and thus species differences may be
implicated, although it is possible that cell phenotype may also
3 W. H. Faour, A. Mancini, Q. W. He, and J. A. Di Battista, manu-
script in preparation.
FIG. 8. rhIL-17-dependent stabilization of COX-2 mRNA and
increased translation is mediated by the distal portion of COX-2
3-UTR. HSF were plated in 12-well cluster plates at 30–40% conflu-
ence in DMEM supplemented with 10% heat-inactivated FCS, 100
units/ml penicillin, and 100 g/ml streptomycin. One g of LUC-3-
UTR, LUC-ARE, LUC-ARE, or LUC-3-UTR and 0.5 g of pCMV--
gal were transfected as described under “Experimental Procedures.”
Following a change in medium containing 1% FCS for 2 h, the trans-
fected cells were treated with vehicle (control) or with 10 ng/ml of
rhIL-17 for 6 h, rinsed, and treated with actinomycin D (1 g/ml) for 30
min, and then fresh medium was added containing either vehicle (Wo),
rhIL-17 (10 ng/ml), rhIL-17 (10 ng/ml) SB202190 (SB, 0.1 mol/liter),
or PGE2 (100 nmol/liter) alone or in the presence of SB202190 (SB, 10
mol/liter) for an additional 4 h (A). The cells were lysed, and the
luciferase activity, -gal activity, and protein content were determined
as described under “Experimental Procedures.” The values are ex-
pressed as the means  S.D. of three determinations in triplicate of
luciferase activity (relative light units) divided by -gal activity (optical
density). Probabilities (p) were calculated by Student’s t test. *, p 
0.0043; **, p  0.0012; ***, p  0.0021 versus control; , p  0.00016;
, p  0.0001 versus rhIL-1; , p  0.0006; &, p  0.013 versus
LUC-ARE rhIL-17. In B, HSF were plated at 30–40% confluence in
complete medium and then transfected with 1 g of LUC-3-UTR.
Following a change in medium containing 1% FCS for 2 h, the trans-
fected cells were treated with vehicle or with 10 ng/ml of rhIL-17 for 6 h,
rinsed, and treated with actinomycin D (1 g/ml) for 30 min, and then
fresh medium was added containing either vehicle (Wo) or rhIL-17 (10
ng/ml) for an additional 2, 4, or 8 h. In C, rinsed and actinomycin
D-treated cells were incubated with vehicle (Wo) or rhIL-17 (10 ng/ml)
in the absence or presence of SB202190 (0.1 M) for an additional 4 h.
Monolayers were extracted for RNA, and 1 g of total RNA was ana-
lyzed for luciferase mRNA and GAPDH mRNA by RT-PCR as described
under “Experimental Procedures.” Representative RT-PCR gels are
shown (n  3).
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be important. For example, we showed that the cytokine could
activate ERK1/2 in human monocyte/macrophage cultures, al-
though this occurred only after 1–2 h of stimulation and did not
coincide with COX-2 induction (12). This of course does not
exclude the regulation of other target genes, and in this regard
IL-17 is known to promote monocyte differentiation (7, 17).
Furthermore, IL-17 is a potent stimulator of T-cell proliferation
and differentiation, suggesting that in cells of lymphoid and
myeloid origin, the mitogenic activity of the cytokine may be
manifested through the MAPK pathway (7, 17, 69).
In summary, IL-17 is a widely acknowledged regulator of the
immune and inflammatory response regulating directly key
target genes like COX-2. The mechanisms controlling the
COX-2 gene delineated in the present study involve highly
coordinated regulation of both DNA-binding (transcriptional)
and RNA-binding (post-transcriptional) proteins and may pro-
vide a molecular paradigm for the control of other IL-17 target
genes. Interleukin-17 could prove to be an excellent therapeutic
target in the clinical management of inflammatory diseases
like RA using, for example, soluble IL-17 receptor preparations.
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